If patients taking chronic medications fully complied with their drug regimens, annual drug revenues in the U.S. could have reached $508 billion in 2011 rather than the actual $320 billion earned that year, an analysis of the revenue potential from increased medication adherence estimates. The difference translates into $188 billion, or a 59% revenue increase.
The report, released by Capgemini Consultants Nov. 26, also extrapolates its estimate of lost revenues to the global market, figuring...